Our lead therapeutic candidate IC14 is an investigational anti-CD14 monoclonal antibody
IC14 regulates pathogenic inflammatory responses to infection and injury, and has great potential across a variety of disease areas. Right now, we are focused on testing its efficacy in the fight against Motor Neurone Disease (MND) or Amyotrophic lateral sclerosis (ALS), and Coronavirus (COVID-19).
We have united world-leaders in medical research, clinical practice and commercialisation.
“The chronic diseases that afflict us as we age are largely the result of inappropriate inflammation, so the ability of IC14 to reset the level of inflammation should be game-changing for these diseases.“
– Director & Chief Scientific Officer, Prof Ian Frazer